Fangda represented Beijing BSCOMC E-TOWN CBC Industrial Investment Fund (the “Buyout Fund”) in its acquisition of a controlling interest in Pediatrix Therapeutics through a combination of acquisitions from existing shareholders and subscription for newly issued shares. Following completion of the transaction, Beijing Peak Pharmaceutical Co., Ltd. (“Beijing Peak Pharmaceutical”), as a portfolio company of the Buyout Fund, holds a controlling interest in Pediatrix Therapeutics. The transaction was completed in April 2026. The Fangda team was led by partners Diana Li and Sherry Xu, with key support from counsel Siyu Chen, associates Grace Dai, Janet Song, Ma Hang, Esther Rao and Jiaxi Wang. Fangda was primarily responsible for conducting legal due diligence, drafting and negotiating the transaction documents, and assisting with the closing.
Buyout Fund is currently one of the largest specialized healthcare-focused buyout funds in China. The Buyout Fund is managed by CBC Group, with CBC Group and Beijing Shunxi Private Equity Fund Management Co., Ltd. acting as co-general partners.
Pediatrix Therapeutics is an innovative pharmaceutical company focused on pediatric therapeutics. Established in 2021, the company has developed strong capabilities in product selection, clinical development, regulatory approval and commercialization, forming a differentiated competitive advantage. It currently has four approved products and five pipeline products under development, covering multiple therapeutic areas including neurology, allergy and dermatology. The acquisition is highly aligned with the Buyout Fund’s strategic vision to build an integrated pharmaceutical platform in Beijing.
Following the transaction, Pediatrix Therapeutics is expected to be deeply integrated with Beijing Peak Pharmaceutical, forming a platform anchored by established commercialized products and driven by an innovative pipeline. Beijing Peak Pharmaceutical has established a mature commercialization team and sales network, while Pediatrix Therapeutics complements this with its strong capabilities in product selection, R&D, and clinical development, thereby completing the full “R&D–manufacturing–commercialization” value chain. Following the integration, the two parties are expected to achieve complementary strengths and expand into broader therapeutic areas, leveraging Beijing Peak Pharmaceutical’s focus on the gastrointestinal field and Pediatrix Therapeutics’ specialization in pediatrics to cover both adult and pediatric markets. This is expected to further expand their presence across multiple specialties, including pediatrics, psychiatry, respiratory, and dermatology.
